A Phase I/II Clinical Trial of SYS6043 Monotherapy or SYS6043 Combined With PD-1/VEGF Bispecific Antibody ± Chemotherapy in the Treatment of Advanced Solid Tumors.

November 16, 2026 updated by: CSPC Megalith Biopharmaceutical Co.,Ltd.

An Open-label, Multicenter Phase I/II Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of SYS6043 Monotherapy or SYS6043 Combined With PD-1/VEGF Bispecific Antibody ± Chemotherapy in Patients With Advanced Solid Tumors.

This is a multicenter phase 1/2 clinical study to evaluate the efficacy and safety of SYS6043 monotherapy or SYS6043 combined with PD-1/VEGF bispecific antibody ± chemotherapy in patients with advanced solid tumors.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

The Phase I study is a a dose-escalation study, comprises dose escalation for the doublet regimen and dose escalation for the triplet regimen. The Phase II study isa cohort expansion study.

Phase I: the dose escalation use a 3+3 design. The doublet regimen consists of SYS6043 + PD-1/VEGF bispecific antibody. The triplet regimen consists of SYS6043 combined with PD-1/VEGF bispecific antibody ± chemotherapy.

The Phase II study will be conducted as an expansion in 6 cohorts, with indications including triple-negative breast cancer, small cell lung cancer, non-small cell lung cancer, etc.

Study Type

Interventional

Enrollment (Estimated)

368

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Be able to understand and voluntarily sign and datethe written ICF prior to any trial-related procedure;
  2. Age 18-75 (inclusive) years;
  3. Histologically or cytologically confirmed advanced/unresectable or metastatic solid tumors(specific cohort requirements apply, including TNBC, SCLC, and driver-gene negative NSCLC based on UICC/AJCC 8th edition staging);
  4. Dose escalation phase: evaluable lesions per RECIST v1.1. Dose expansion phase: at least one extracranial measurable lesion per RECIST v1.1. Lesions previously treated with radiotherapy or other local therapy may not be selected as target lesions unless there is clear evidence of progression.
  5. Qualified archived or fresh tumor tissue samples must be provided; participants who cannot provide tumor samples or whose samples are insufficient may be enrolled based on individual circumstances.
  6. Eastern Cooperative Oncology Group (ECOG) performance status score: 0-1;
  7. Adequate organ and bone marrow function within 7 days prior to the first dose, as defined below.
  8. Life expectancy ≥ 3 months;
  9. Female participants of childbearing age must have a negative serum pregnancy test within 7 days before dosing. Male and female participants of reproductive potential must agree to use adequate contraception during the study and for at least 7 months after the last dose of the investigational product; during this period, female participants must not be breastfeeding, male participants must not freeze or donate sperm, and female participants must not donate eggs or undergo egg retrieval for personal use.

Exclusion Criteria:

  1. Combined SCLC (i.e., mixed large cell carcinoma, squamous cell carcinoma, spindle/pleomorphic and/or large cell components) and transformed SCLC.
  2. Prior history of CTCAE grade ≥3 immune-related adverse events (irAEs) during treatment with anti-PD-(L)1 or other immune checkpoint inhibitors, immune checkpoint agonists, immune cell therapy, or other therapies targeting tumor immune mechanisms, except for endocrine disorders such as hyperglycemia or hypothyroidism that have recovered to grade ≤2.
  3. Prior treatment with B7-H3-targeted therapies (including antibodies, antibody-drug conjugates [ADCs], chimeric antigen receptor T-cell [CAR-T] therapies, and other agents).
  4. Prior treatment with a topoisomerase I inhibitor antibody-drug conjugate or a topoisomerase I inhibitor.
  5. Toxicities from prior antitumor therapy have not resolved to CTCAE grade ≤1 or to the levels specified in the inclusion/exclusion criteria (except alopecia and hyperpigmentation).
  6. History of underlying pulmonary disease, including but not limited to severe asthma, severe COPD, restrictive lung disease, and other clinically significant pulmonary impairment or requirement for supplemental oxygen.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: SYS6043+PD-1/VEGF bispecific antibody

SYS6043: IV PD-1/VEGF bispecific antibody: IV

Experimental: SYS6043 combined with PD-1/VEGF bispecific antibody +chemotherapy.

SYS6043: IV PD-1/VEGF bispecific antibody: IV Chemotherapy: cisplatin or carboplatin, IV

Experimental: SYS6043 monotherapy

SYS6043: IV

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Phase I: Incidences of AEs
Time Frame: From the signing of the informed consent form until 90 days after the last dose.
From the signing of the informed consent form until 90 days after the last dose.
Phase I: DLT
Time Frame: 21 days

Dose-limiting toxicity

21 days
Phase I: MTD/RP2D
Time Frame: After phase I dose escalation stage. Approximately 4 months.

Maximum Tolerated Dose/ Recommended Phase II Dose

After phase I dose escalation stage. Approximately 4 months.
Phase II: ORR
Time Frame: Up to 2 years

Objective response rate

Up to 2 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Phase I: ORR
Time Frame: Up to 2 years

Objective response rate

Up to 2 years
Phase I:DCR
Time Frame: Up to 2 years

Disease control rate

Up to 2 years
Phase I:DOR
Time Frame: Up to 2 years

Duration of response

Up to 2 years
Phase I: TTR
Time Frame: Up to 2 years

Time to Response

Up to 2 years
Phase I: PFS
Time Frame: Up to 2 years

Progression free survival

Up to 2 years
Phase I:OS
Time Frame: Up to 3 years

Overall survival

Up to 3 years
Phase I:Plasma concentrations of SYS6043, total antibody, and free JS-1.
Time Frame: Up to 2 years
Up to 2 years
Phase I:Incidence of anti-drug antibodies (ADAs) and neutralizing antibodies (NAbs) for SYS6043.
Time Frame: Up to 2 years
Up to 2 years
Phase I:Expression levels of proteins such as B7-H3 and PD-L1 in tumor tissue.
Time Frame: Up to 2 years
Up to 2 years
Phase II:DCR
Time Frame: Up to 2 years

Disease control rate

Up to 2 years
Phase II:DOR
Time Frame: Up to 2 years

Duration of response

Up to 2 years
Phase II: TTR
Time Frame: Up to 2 years

Time to Response

Up to 2 years
Phase II: PFS
Time Frame: Up to 2 years

Progression free survival

Up to 2 years
Phase II:OS
Time Frame: Up to 3 years
Up to 3 years
Title: Phase II: Incidences of AEs
Time Frame: From the signing of the informed consent form until 90 days after the last dose.

Overall survival

From the signing of the informed consent form until 90 days after the last dose.
Phase II:Plasma concentrations of SYS6043, total antibody, and free JS-1.
Time Frame: Up to 2 years
Up to 2 years
Phase II:Incidence of anti-drug antibodies (ADAs) and neutralizing antibodies (NAbs) for SYS6043.
Time Frame: Up to 2 years
Up to 2 years
Phase II:Expression levels of proteins such as B7-H3 and PD-L1 in tumor tissue.
Time Frame: Up to 2 years
Up to 2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 30, 2026

Primary Completion (Estimated)

December 30, 2028

Study Completion (Estimated)

December 30, 2029

Study Registration Dates

First Submitted

November 13, 2026

First Submitted That Met QC Criteria

November 16, 2026

First Posted (Actual)

November 20, 2026

Study Record Updates

Last Update Posted (Actual)

November 20, 2026

Last Update Submitted That Met QC Criteria

November 16, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • SYS6043-005

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.